SCHEMBL25533451

SCHEMBL25533451

COC(=O)c1ncc(C)n(-c2ccc(F)cn2)c1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
RAB9A P51151 4/20 0.36
ALDH1A1 P00352 3/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
HSD17B10 Q99714 1/20 0.35
GRM5 P41594 2/20 0.34
NPC1 O15118 2/20 0.34
CASP3 P42574 1/20 0.34
SENP8 Q96LD8 1/20 0.34
SENP7 Q9BQF6 1/20 0.34
SENP6 Q9GZR1 1/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
HRH3 Q9Y5N1 1/20 0.34
MAPK14 Q16539 3/20 0.34
MAPT P10636 1/20 0.33
GABRA5 P31644 1/20 0.33
CNR1 P21554 1/20 0.33
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30063313 1.00 KDM4E (0.40) KDM4EL3MBTL1RAB9AALDH1A1SMN1; SMN2
SCHEMBL23147647 0.85 KDM4E (0.50) KDM4EL3MBTL1ALDH1A1GRM5KMT2A
SCHEMBL25529134 0.85 L3MBTL1 (0.38) KDM4EL3MBTL1RAB9AALDH1A1GRM5
SCHEMBL30174170 0.85 MYC (0.36) KDM4EL3MBTL1ALDH1A1SMN1; SMN2GRM5
SCHEMBL25227025 0.85 MYC (0.36) KDM4EL3MBTL1ALDH1A1SMN1; SMN2GRM5
SCHEMBL30174285 0.84 KDM4E (0.36) KDM4EL3MBTL1ALDH1A1GRM5HRH3
SCHEMBL25533553 0.78 KDM4E (0.42) KDM4EL3MBTL1RAB9AALDH1A1SMN1; SMN2
SCHEMBL25529136 0.75 MAPK14 (0.40) KDM4EL3MBTL1RAB9AALDH1A1NPC1
SCHEMBL25528981 0.71 MYC (0.42) KDM4EL3MBTL1ALDH1A1KMT2AMEN1
SCHEMBL594708 0.71 KMT2A (0.50) L3MBTL1SMN1; SMN2HSD17B10KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230151003-A1 COMPOUNDS AND METHODS OF USE EXELIXIS INC (US) 2023-05-18 US disclosed
CN-115605478-A Compounds and methods of use 埃克塞里艾克西斯公司(US) 2023-01-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151003-A1 COMPOUNDS AND METHODS OF USE PRKACB, PRKACA, PRKX KDM4E 3309/4885L3MBTL1 3091/4885RAB9A 2620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.